BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
AstraZeneca
Harvard Business School
Queensland Health
Healthtrust
Cipla
Fish and Richardson
Julphar
Accenture
Colorcon

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,637,512

« Back to Dashboard

Which drugs does patent 8,637,512 protect, and when does it expire?

Patent 8,637,512 protects LAMICTAL XR and is included in one NDA.

This patent has forty patent family members in thirty countries.
Summary for Patent: 8,637,512
Title:Formulations and method of treatment
Abstract: A sustained release formulation of lamotrigine or a pharmaceutically acceptable derivative thereof and methods of treatment and uses thereof.
Inventor(s): Buxton; Ian Richard (Mississauga, CA), Karolak; Wlodzimierz (Mississauga, CA), Maleki; Mehran (Mississauga, CA), Iyer; Vijay Mohan (Mississauga, CA)
Assignee: Glaxo Group Limited (Brentford, Middlesex, GB)
Application Number:10/726,752
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 8,637,512

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-001 May 29, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-002 May 29, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-003 May 29, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-004 May 29, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-006 Jun 21, 2011 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-005 Apr 14, 2010 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,637,512

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0217492.8Jul 29, 2002
United Kingdom0217493.6Jul 29, 2002
United Kingdom0313801.3Jun 13, 2003

International Patents Family Members for US Patent 8,637,512

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 100363007 ➤ Subscribe
China 101229169 ➤ Subscribe
Colombia 5680405 ➤ Subscribe
Cyprus 1109119 ➤ Subscribe
Germany 60326590 ➤ Subscribe
Denmark 1524981 ➤ Subscribe
European Patent Office 1524981 ➤ Subscribe
Japan 4744142 ➤ Subscribe
Spain 2323268 ➤ Subscribe
United Kingdom 0217492 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
McKesson
Argus Health
Chubb
Dow
US Department of Justice
Daiichi Sankyo
Cerilliant
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot